Background
First identified as pseudogout by McCarty et al. in 1962 [
1‐
3], calcium pyrophosphate crystal deposition (CPPD) is a collective term proposed by Ryan and McCarty in 1985 [
4] and later acknowledged by the European Alliance of Associations for Rheumatology (EULAR) task force. It comprises all forms of CPP crystal-induced arthropathies [
5]. CPPD is characterized by the deposition of CPP crystals in various intra-articular and/or periarticular tissues, resulting in acute noninfectious inflammatory and degenerative chronic arthropathies and cartilaginous calcifications [
6,
7]. CPPD commonly involves large joints such as the knee, shoulder, hip, and wrist and rarely affects small joints such as the temporomandibular joint (TMJ) [
8]. CPPD in the TMJ, a complex diarthrodial sliding-ginglymoid synovial joint between the glenoid fossa of the temporal bone and the mandibular condyle, was first described in 1976 by Pritzker et al. [
9]. Nonetheless, from a general perspective on its etiopathology, the majority of CPPD cases are of non-genetic type, with partially established etiology (primary idiopathic subtype) and various predisposition factors implicated. For instance, advanced age (> 60 years), osteoarthritis, joint trauma, and metabolic diseases such as hyperparathyroidism, hypothyroidism, hypomagnesemia, hyperphosphatemia, and diabetes mellitus are usually proposed as contributing factors [
8,
10‐
12]. CPPD cases of genetic (familial) type are notably rare, autosomal dominant, and mostly associated with early onset, before the age of 55 years [
10]. Multiple studies have identified familial CPPD to have genetic linkages to A1 B12 DR3 human leukocyte antigen (HLA) haplotype and chromosomal region 8q, previously dubbed chondrocalcinosis 1 or chondrocalcinosis with early-onset osteoarthritis (CCAL1) type, and chromosomal region 5p5.1 referred to as chondrocalcinosis 2 (CCAL2) type [
13‐
15]. Specific HLA-associated gene mutations and chromosome 8q-linked CCAL1 are still unknown. However, CCAL2 is reportedly mediated by mutations in the progressive ankylosis protein homolog human gene (
ANKH) [
10,
16]. These gain-of-function mutations affect the regulation of intracellular and extracellular inorganic pyrophosphate (PPi) cellular transporter, subsequently increasing the
ANKH activity. The increased activity leads to the accumulation of PPi in the cartilage, which in combination with calcium results in CPP crystal formation [
17]. Furthermore,
ANKH mutations also contribute, at least in part, to the pathophysiology of the non-genetic CPPD type [
16]. The deposited CPP crystals trigger NALP-3 inflammasome, a Nod-like receptor, and caspase-1-containing cytoplasmic multiprotein complex, to assemble, process, and activate proinflammatory cytokines interleukin (IL)-1
β and IL-18, which eventually cause joint inflammation [
18].
CPPD of the TMJ poses diagnostic challenges; a likely justification for its rarity in the literature [
19‐
21]. Although the diagnosis of CPPD is based on described criteria [
22], highlighted in Table
1, the identification of parallelepipedic, principally cellular deposits of crystals with absent or weak positive birefringence in the synovial fluid or tissue of the affected joint (criterion IIa) may be challenged by the presence of other birefringent crystals such as calcium oxalate, synthetic steroids, and ethylenediaminetetraacetic acid in the joint fluids and tissues [
23,
24].
Table 1
Diagnostic criteria for CPP crystal deposition
I | Proof of calcium pyrophosphate crystals by x-ray diffraction or chemical analysis |
IIa | Corrected polarization microscopy confirms triclinic and monoclinic crystals showing weak positive birefringence |
IIb | Typical calcification image on x-ray |
IIIa | Acute arthritis |
IIIb | Chronic arthritis |
IIIb1 | Arthritis in areas where primary OA is usually rare |
IIIb2 | Narrowing of the joint cleft of the radial carpal joint or patellofemoral joint |
IIIb3 | Subchondral cyst |
IIIb4 | Severe progressive degeneration with subchondral bony subsidence and fragmentation with intra-articular radiopaque bodies |
IIIb5 | Variable osteophyte formation |
IIIb6 | Tendon calcification |
IIIb7 | Axial skeletal lesions, subchondral cysts of the epiphyseal and sacroiliac joints, intervertebral disc calcification and vacuum phenomena in multiple vertebral bodies, sacroiliac vacuum phenomena |
Synovial chondromatosis (SC) is a rare benign joint neoplasm that is associated with the metaplastic proliferation of cartilaginous nodules within the synovial membrane that commonly manifests as intraarticular loose bodies. Although very rare, with a prevalence of approximately 1 per 100,000, loose bodies can form within extraarticular spaces, resulting in a condition referred to as tenosynovial chondromatosis [
25‐
27]. SC affects approximately 1.8 per 1 million individuals, the majority of whom are in their third or fifth decade of life, with an unequal sex ratio, i.e., with a preponderance of men over women. In addition, SC commonly affects the knee and hip in nearly 90% of published cases, but rarely affects the TMJ [
28]. Although surgical management, the gold standard treatment for SC, is associated with a high success rate, local recurrence rates of 15–20% have been reported, especially in tenosynovial cases [
28]. Moreover, malignant transformation to synovial chondrosarcoma can occur particularly in long-standing disease and multiple recurrence cases but is reportedly extremely rare [
29]. Similar to CPPD, the etiopathogenesis of SC is unknown. However, several reports have suggested that SC can be either primary, also referred to as Reichel syndrome, primary synovial osteochondromatosis, or Reichel–Jones–Henderson syndrome, or result from (secondary) degenerative intraarticular changes, joint trauma, and inflammatory events such as neuropathic arthritis and osteochondritis dissecans [
27,
30‐
33]. In their recent report, Agaram, et al. [
29] well summarized the genetic alterations identified in SC, which most likely play a role in the disease etiopathology. The genetic alterations include the previously identified
Fibronectin 1 (
FN1)–
Activin receptor 2A (
ACVR2A) gene fusions, which were first identified in SC and reported by Totoki et al. [
34] and later demonstrated by several separate molecular studies using various techniques [
29]. The authors have also identified a novel lysine (K)-specific methyltransferase 2A (
KMT2A)–BCL6 corepressor (
BCOR) gene fusion in a rare case of tenosynovial chondromatosis [
29].
The clinical presentation of SC that involves three cardinal signs and symptoms was previously described [
35]. The signs and symptoms include preauricular pain, swelling, facial asymmetry, crepitation, joint deformity, and dysfunction, as well as the unilateral deviation of the jaw during mouth opening. Radiology is very useful in demonstrating SC’s features for diagnosis and treatment plans [
22,
36‐
38]. The specific radiographic diagnostic criteria for SC include joint space widening, limitation of motion, irregularity of joint surfaces, presence of calcified loose bodies, and sclerosis of the glenoid fossa and mandibular condyle [
39]. The histopathological classification of SC has been described [
40] and presented in Table
2.
Table 2
Histopathological classification of synovial chondromatosis
Phase 1 | Cartilaginous tissue formation takes place (active synovitis) without loose bodies |
Phase 2 | Presence of both chondrosynovial changes and intraarticular loose bodies (i.e., nodular synovitis with loose bodies) |
Phase 3 | Completion of cartilaginous ossification and presence of loose bodies only (i.e., loose bodies with resolution of synovitis) |
Simultaneous occurrence of CPPD and SC is rarely reported in the TMJ [
3,
41,
42]. Herein, we present this unusual TMJ comorbidity in a 61-year-old Japanese man, delineate the molecular etiopathology of these diseases, reiterate the importance of confirmatory testing in minimizing diagnostic limitations and discuss surgery with the removal of lesions and synovectomy as the preferred choice of treatment. We present the case report following the CARE case report guidelines [
43].
Discussion and conclusions
TMJ is indispensable to key facial activities such as jaw mobility, mastication, and verbal and emotional expression. CPPD and CS are among inflammatory arthropathies and neoplasm pathologies respectively, which commonly contribute to the annual incidence (4%) and prevalence (5–31%) of chronic TMJ pain, which is an economic burden to society [
46,
47]. CPPD of the TMJ is generally rare, with only a few case reports published in the literature due to the associated difficulties in diagnosis [
23,
24]. In contrast, although SC of the TMJ was previously considered a rare condition, the recent technological advancement in radiology dramatically minimized the diagnostic challenges and improved publication [
22]. However, the coexistence of both CPPD and SC in the TMJ remains a rare condition [
48].
A definitive diagnosis of CPPD is based on the presence of criteria I–IIb and considered likely with IIa–IIIb, as shown in Table
1. In the present case, although further diagnostic approaches, such as XRD and chemical analysis were not conducted, the patient had a great predisposition to DM, and concomitant clinical features such as chronic TMJ pain, in addition to the crystal deposition of previously described appearance [
1‐
4], that displayed positive birefringence in polarized light (IIa). Moreover, CT, the best imaging modality for the disease revealed a typical calcification image (IIb), thus confirming the diagnosis of CPPD. Advanced imaging modalities, such as CT and MRI are very useful in making a reliable diagnosis and treatment plan for SC based on the criteria previously described [
22,
36‐
38] and the histopathological classification shown in Table
2. In the present case, the patient had no history of trauma before the onset of illness, and radiology revealed joint effusion with multiple calcified loose bodies in a tumor-like lesion of approximately 38 mm with a well-defined border surrounding the mandibular condyle of the right TMJ. Moreover, histopathology confirmed the presence of only loose bodies, suggesting SC of phase III classification (Table
2). No evidence of malignancy or chondrosarcoma was observed in the patient and the findings of calcified loose bodies ruled out PVNS.
Therefore, taken together, the aforementioned findings suggested a coexistence of CPPD and SC in the right TMJ in the present case, the rare pathology. The mechanism by which SC and CPPD coexist is not well understood [
3,
41,
42]. CPPD, a noninfectious inflammatory arthropathy could result from joint overloading, trauma, comorbidities such as metabolic disorders, osteoarthritis, and other TMJ disorders and later mediates SC [
46]. On the other hand, primary SC characterized by chondrocyte differentiation of synovial pluripotent stem cells, and chondroid tissue production of unknown cause may simply occur in tandem with a familial CPPD [
10]. The present case had a possibility of DM comorbidity and class III malocclusion, attributable to either primary SC or bruxism-induced stress, leading to the development of CPPD.
A recent report by Stack and Geraldine [
49] well summarized and discussed the treatment options for CPPD. There currently are no CPPD- modifying therapies that can reduce articular calcification. Available pharmacological treatments aim to mitigate inflammation and symptoms' frequency and severity. The therapies include non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids that reduce the symptoms of CPPD. Anakinra and tocilizumab are recommended as a treatment for severe, refractory CPPD by EULAR. While crystal-targeted treatments such as nucleoside analogues and phosphocitrate are still under study but promising in attenuating calcification of human cartilage. Primary SC is treated with surgery including open or arthroscopic synovectomy and loose body resection due to severe symptoms that impact AROM [
50]. Additional joint reconstruction or arthroplasty is recommended to prevent re-occurrence and degenerative joint disease. Secondary SC is treated with NSAIDs, and when symptoms persist or worsen, surgery is indicated.
The coexistence of both SC and CPPD is managed through excision of the lesion, anti-inflammatory therapy with NSAIDs, cleansing therapy, and follow-up. Excision of the loose bodies and pathological synovium is necessary, and some reports suggest that mandibulectomy is required if the lesion is large and invasive. However, Blankestijn et al. [
51] reported that lesions rarely involve the mandibular head and do not necessarily require a mandibulectomy. Milgram [
31,
40] also reported that synovectomy is not necessary for the final part of the third stage of the histopathological classification of SC. However, in the present case, surgery involved the complete removal of the loose bodies, CPPD lesions, and synovectomy to minimize the risk of recurrence. In addition, the arguable causal relationship between CPPD and SC of the TMJ suggested pathologically predisposed synovium and therefore, an indication for removal. The patient had been followed up for 1.5 years after surgery, without any post-surgery sequelae observed. However, because of the likelihood of persistent malocclusion and previously reported TMD recurrences [
52,
53], an extended follow-up including a validated DC/TMD assessment of the patient has been planned.
In summary, although isolated cases of CPPD and SC of the TMJ are more prevalent in the literature, a monoarticular coexistence of these diseases is rare. This is often attributed to factors such as difficulties in diagnosing TMJ diseases, despite the advances in imaging technology and the reported interest in research and application of several different diagnostic approaches. Moreover, optimal treatment depends on several considerations. The present case delineated the molecular etiopathology of CPPD and SC and unveiled the need for continued deciphering mechanisms leading to the diseases' coexistence in the TMJ. In addition, the importance of confirmatory testing for accurate diagnosis was recapitulated and, in our opinion, appropriate management of the case was considered.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.